Personalized Medicine Care (PMC™), former PMCDx, announced that the American Medical Association (AMA) has voted to approve new Proprietary Laboratory Analyses (PLA) code for the company’s RenaDx™ comprehensive kidney genetic testing panel, marking a major milestone for the company and the renal genetics field.
At present, only a few companies such as Natera provide comprehensive genetic testing for kidney disease. With this latest approval, PMC™ stands out as the only laboratory to offer an AMA-recognized panel specifically designed for kidney disease, setting a new benchmark for clinical credibility, diagnostic accuracy, and innovation in the field of nephrogenomics.
PMC™ also offers RenaXome™, a reflex test that leverages whole exome sequencing to aid in the diagnosis of complex kidney conditions. The decision follows unanimous support from the AMA advisory committee, which also provides recommendations to CMS (Centers for Medicare & Medicaid Services) regarding coverage determinations.
The new approval comes amid growing clinical consensus that genetic testing provides significant value in nephrology. Current guidelines recommend genetic testing for a broad range of kidney disorders, with studies showing that up to 40% of cases can be explained by genetic findings, offering high clinical utility and predictive value that can inform patient management and treatment pathways.
This milestone positions PMC™ to directly compete for major clinical-trial and precision-medicine partnerships in renal disease. Leading biopharmaceutical companies,including Vertex and Novo Nordisk,currently leverage genetic panels to identify and enroll participants in kidney-disease studies. With AMA recognition, PMC™’s RenaDx™ panel can now support similar initiatives, expanding access and driving innovation in renal health.
PMC™ is also advancing precision medicine with novel, technology-driven testing panels, including pharmacogenetics assays for patients with hypertension and cardiovascular–kidney–metabolic (CKM™) conditions, as well as RenaPGx™ for transplant patients. Together, these solutions enable precision therapeutic decision-making, helping clinicians optimize treatment and reduce adverse drug events.
